Protalix BioTherapeutics

Sensei Biotherapeutics to Participate in Upcoming Investor Conferences

Retrieved on: 
星期三, 八月 30, 2023
Cancer, Protalix BioTherapeutics, Therapy, Patient, Pharmaceutical industry, Financial services

BOSTON, Aug. 30, 2023 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical stage immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer patients, today announced that Company management will participate in the following investor conferences in September 2023:

Key Points: 
  • BOSTON, Aug. 30, 2023 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical stage immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer patients, today announced that Company management will participate in the following investor conferences in September 2023:
    Portfolio managers and analysts who would like to request a meeting with management should contact their representative at the respective hosting firms.

Fabry Disease Industry Insights 2023-2032: Epidemiology, Drug Pipeline, Emerging Treatments, Market Trends, Expert Opinions - ResearchAndMarkets.com

Retrieved on: 
星期五, 八月 25, 2023
Health, Other Health, EU4, Subject-matter expert, Chiesi Farmaceutici, Internet, USD, AAV, Protalix BioTherapeutics, ERT, GLA, Sangamo Therapeutics, Growth, Late onset congenital adrenal hyperplasia, Classic, Enzyme replacement therapy, Epidemiology, PEGylation, SME, Pharmaceutical industry, Vaccine, Video game, Dentistry, Fabry, EU, Fabry disease

This comprehensive analysis offers valuable insights into the Fabry Disease market, including epidemiology, drug pipeline, emerging treatments, market trends, and expert opinions, ultimately assisting stakeholders in understanding the evolving landscape and potential opportunities.

Key Points: 
  • This comprehensive analysis offers valuable insights into the Fabry Disease market, including epidemiology, drug pipeline, emerging treatments, market trends, and expert opinions, ultimately assisting stakeholders in understanding the evolving landscape and potential opportunities.
  • The report provides a comprehensive understanding of Fabry Disease epidemiology, including historical and forecasted data.
  • The Fabry Disease market experienced 15,290 diagnosed prevalent cases in the 7MM in 2022, with 8,355 cases in the US alone.
  • The Fabry Disease market size is projected to increase at a CAGR of 6.3% from 2023 to 2032, driven by awareness and the launch of emerging drugs.

Protalix BioTherapeutics Reports Second Quarter 2023 Financial and Business Results

Retrieved on: 
星期一, 八月 7, 2023
Protalix BioTherapeutics, Medsafe, European Medicines Agency, Tax, MD, Patient, European, Fabry disease, BLA, NYSE, Calendar, Gout, Half-life, Pharmacokinetics, Research, EMA, Russell, FIH, Growth, FDA, PEGylation, Biologics license application, Safety, Civil service commission, Health, Baylor University Medical Center, Israel Innovation Authority, FASN, Webcast, MAA, HDEC, European Commission, KOL, Clinical trial, EDT, Marketing, ERT, EC, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Food, Vaccine, Pharmaceutical industry, Drug, Life insurance, Online shopping, EU, Fabry, Chiesi Farmaceutici

CARMIEL, Israel, Aug. 7, 2023 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx® plant cell-based protein expression system, today reported financial results for the second quarter ended June 30, 2023 and provided a business update on recent regulatory, clinical and corporate developments.

Key Points: 
  • "2023 has been a transformational year for Protalix thus far," said Dror Bashan, Protalix's President and Chief Executive Officer.
  • On May 5, 2023, the European Commission (EC) granted marketing authorization to Elfabrio (pegunigalsidase alfa) in the European Union.
  • On June 26, 2023, the Company was included in the broad-market Russell 3000® Index at the conclusion of the 2023 Russell indexes annual reconstitution.
  • Financial expenses, net were $0.8 million for the three months ended June 30, 2023, compared to financial income, net of $0.2 million for the three months ended June 30, 2022.

Codexis Reports Second Quarter 2023 Financial Results

Retrieved on: 
星期四, 八月 3, 2023
Enzyme, Probability, MBBS, Therapy, RNA, Medication, Research, Doctor of Philosophy, Small RNA, RNA interference, Patient, ECO, Administration, General Administration of Customs, Fine chemical, Video game, Pharmaceutical industry, Protalix BioTherapeutics, Codexis

REDWOOD CITY, Calif., Aug. 03, 2023 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today announced financial results for the second quarter ended June 30, 2023, and provided a business update.

Key Points: 
  • REDWOOD CITY, Calif., Aug. 03, 2023 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today announced financial results for the second quarter ended June 30, 2023, and provided a business update.
  • Including enzyme sales related to PAXLOVID™, total revenues were $21.3 million in second quarter 2023 compared to $38.4 million in second quarter 2022.
  • Including enzyme sales related to PAXLOVID™, product revenues were $11.0 million in second quarter 2023 compared to $34.6 million in second quarter 2022.
  • Product gross margin for second quarter 2023 was 71% compared to 67% in second quarter 2022; the increase was largely driven by variability in the product mix which was partially offset by revenue recognized with no related cost in the second quarter of 2023.

Protalix BioTherapeutics to Present at the Canaccord Genuity 43rd Annual Growth Conference

Retrieved on: 
星期二, 八月 1, 2023
Calendar, Canaccord Genuity, Protalix BioTherapeutics, Bashan, EDT, Webcast, Conference

CARMIEL, Israel, Aug. 1, 2023 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American:PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx® plant cell–based protein expression system, today announced that Dror Bashan, the Company's President and Chief Executive Officer, will present on Wednesday, August 9, 2023 at 3:30 p.m. Eastern Daylight Time (EDT) at the Canaccord Genuity 43rd Annual Growth Conference.

Key Points: 
  • CARMIEL, Israel, Aug. 1, 2023 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American:PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx® plant cell–based protein expression system, today announced that Dror Bashan, the Company's President and Chief Executive Officer, will present on Wednesday, August 9, 2023 at 3:30 p.m. Eastern Daylight Time (EDT) at the Canaccord Genuity 43rd Annual Growth Conference.
  • The conference is being held on August 7-10, 2023 at the InterContinental Boston Hotel, Boston, MA.
  • Mr. Bashan will provide a live corporate overview at the conference, and the Company's management will participate in one-on-one meetings on August 7-9 with investors who are registered to attend the conference.
  • A live and archived webcast of Mr. Bashan's presentation will be available as follows:
    Live Presentation and Webcast Details:
    The webcast will be available for replay for at least two weeks on the Events Calendar of the Investors section of the Company's website, https://protalixbiotherapeutics.gcs-web.com/events0 .

Protalix BioTherapeutics to Announce Second Quarter 2023 Financial and Business Results on August 7, 2023

Retrieved on: 
星期一, 七月 31, 2023
Webcast, Calendar, NYSE, Protalix BioTherapeutics, EDT

CARMIEL, Israel, July 31, 2023 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx® plant cell–based protein expression system, today announced that it will release its financial results for the second quarter ended June 30, 2023 and provide a business update on Monday, August 7, 2023.

Key Points: 
  • Company to host conference call and webcast at 8:30 a.m. EDT
    CARMIEL, Israel, July 31, 2023 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx® plant cell–based protein expression system, today announced that it will release its financial results for the second quarter ended June 30, 2023 and provide a business update on Monday, August 7, 2023.
  • Management will host a conference call with investors to discuss the financial results and provide an update on recent corporate and regulatory developments at 8:30 a.m. Eastern Daylight Time (EDT).
  • The Call me™ feature, which avoids having to wait for an operator, may be accessed at the following link: https://tinyurl.com/2v682k5m .
  • A replay of the call will be available for two weeks on the Events Calendar of the Investors section of the Company's website, at the above link.

Codexis Announces Enhanced Strategic Focus and Extends Projected Cash Runway to Mid-2026

Retrieved on: 
星期四, 七月 20, 2023
Workforce, DNA, EPI, Probability, MBBS, Therapy, Exocrine pancreatic insufficiency, Bank statement, RNA, Ligation, Enzyme, Medication, Doctor of Philosophy, Messenger, Pharmaceutical manufacturing, Small RNA, RNA interference, Metabolism, Patient, ECO, Administration, Engineering, Growth, Conference, Fine chemical, Risk management, Pharmaceutical industry, Cryptocurrency, Protalix BioTherapeutics, Codexis

REDWOOD CITY, Calif., July 20, 2023 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today announced that, in alignment with its previously announced strategy to focus resources on programs with the strongest probability of creating significant value in the near-term and beyond, the Company intends to prioritize the advancement and commercialization of its Enzyme-Catalyzed Oligonucleotide (ECO) Synthesis™ platform and its highly complementary Pharmaceutical Manufacturing business. As part of this enhanced strategic focus, the Company is streamlining operations, including discontinuing investment in certain development programs, primarily in Biotherapeutics, consolidating operations to its headquarters and reducing headcount by approximately 25%. Codexis had $92.1 million in cash and cash equivalents as of June 30, 2023, and with these changes expects that this balance will be sufficient to fund its planned operations to mid-2026, providing the Company the opportunity to deliver on critical milestones related to its ECO Synthesis™ platform.

Key Points: 
  • As part of this enhanced strategic focus, the Company is streamlining operations, including discontinuing investment in certain development programs, primarily in Biotherapeutics, consolidating operations to its headquarters and reducing headcount by approximately 25%.
  • We believe Codexis is uniquely positioned to design and bring to market an enzymatic solution that addresses this challenge.
  • As of June 30, 2023, the Company had cash and cash equivalents of $92.1 million.
  • As of June 30, 2023, the Company had an estimated $92.1 million in cash and cash equivalents.

Excision BioTherapeutics Receives FDA Fast Track Designation for EBT-101, a First-in-Class CRISPR-Based Gene Therapy Candidate to Functionally Cure HIV-1

Retrieved on: 
星期四, 七月 20, 2023
CRISPR, US Foods, HIV, HIV-1, ART, Fast Track, Protalix BioTherapeutics, Genome, Social stigma, Risk, SAN, FDA, Food, Safety, Disease, Pharmaceutical industry

Fast Track designation is intended to facilitate the development and expedite the review of potentially important new drugs to treat serious conditions with unmet medical needs.

Key Points: 
  • Fast Track designation is intended to facilitate the development and expedite the review of potentially important new drugs to treat serious conditions with unmet medical needs.
  • Therapies granted this designation are given the opportunity for more frequent interactions with the FDA and may qualify for other designations including accelerated approval and priority review.
  • Daniel Dornbusch, Chief Executive Officer of Excision, said, “We are pleased with the FDA’s decision to grant Fast Track designation to EBT-101.
  • Without a cure, the current standard of care is antiretroviral therapy (ART) that must be taken for the duration of an individual's life.

Trestle Biotherapeutics Wins Prestigious KidneyX Prize

Retrieved on: 
星期一, 六月 12, 2023
Health, Diabetes, Stem Cells, Health Technology, Other Health, General Health, Biotechnology, Tissue, Protalix BioTherapeutics, Cleveland Clinic, Partnership, Kidney failure, Chronic kidney disease, U.S. Department of Defense Strategy for Operating in Cyberspace, HHS, Artificial kidney, Office of Inspector General, U.S. Department of Health and Human Services, 3D, Survival, American Society of Nephrology, Dialysis, ASN, Patient, Kidney, Diagnosis, Cleveland, CKD, Society, Pharmaceutical industry, Trestle

Trestle Biotherapeutics today received a $1 million prize from the KidneyX Innovation Accelerator through the organization’s Artificial Kidney Prize program.

Key Points: 
  • Trestle Biotherapeutics today received a $1 million prize from the KidneyX Innovation Accelerator through the organization’s Artificial Kidney Prize program.
  • Trestle is one of eight Artificial Kidney Prize Phase 2 winners announced today.
  • Trestle was recognized for their innovative approach in developing bioengineered kidney tissues for patients living with kidney failure through the integration of cutting-edge techniques in stem cell biology and 3D biofabrication.
  • Of the work being done at Trestle, John Sedor, M.D., KidneyX Chair and nephrologist at the Cleveland Clinic, said, “We are thrilled to support ambitious, forward-thinking solutions for kidney failure patients like the ones being developed at Trestle Bio.

EpimAb Biotherapeutics Appoints Yonghong Zhu, M.D., Ph.D., as Chief Medical Officer

Retrieved on: 
星期四, 六月 8, 2023
Science, Other Science, Biotechnology, Research, Pharmaceutical, Oncology, Health, Other Health, Medical degree, Monoclonal antibody, Protalix BioTherapeutics, University, Doctor of Philosophy, Takeda, Roche, CMO, Nanjing University Medical School, Translational medicine, Medicine, Medical device, Virology

EpimAb Biotherapeutics , a clinical stage biotechnology company specializing in the development of bispecific antibodies, today announced the appointment of Yonghong Zhu, M.D., Ph.D., as Chief Medical Officer (CMO).

Key Points: 
  • EpimAb Biotherapeutics , a clinical stage biotechnology company specializing in the development of bispecific antibodies, today announced the appointment of Yonghong Zhu, M.D., Ph.D., as Chief Medical Officer (CMO).
  • As CMO, Dr. Zhu will be responsible for overseeing all clinical development activities for the company’s clinical stage assets.
  • Dr. Zhu replaces EpimAb’s previous CMO, Dr. Bin Peng, who recently retired from EpimAb after five years of service at the company.
  • "We are excited to welcome Dr. Zhu as our new Chief Medical Officer," said Dr. Chengbin Wu, Founder and CEO of EpimAb.